Microbot Medical Inc Stock News

The addition of a seasoned VP of Marketing compliments the recent hiring of the Company's VP of Sales to establish its commercialization readiness infrastructure

Successful robotic navigation was achieved in every case and  met the primary endpoint of the study LIBERTY ® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-P...

Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter

Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year

BRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced its collaboration with Corewell Health™ has reached another meaningful milestone.

BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 shares of the Company's common stock at a purchase price of $2.13 per share of common stock. In addition, in a concurrent private placement, the C...

BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 6,103,289 shares of the Company's common stock at a purchase price of $2.13 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private plac...

BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company's common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the C...